Dr. Pollack on the Potential Impact of Radiomics on the Sarcoma Treatment Landscape

Video

In Partnership With:

Seth M. Pollack, MD, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the potential impact that radiomics could have on the treatment landscape of sarcoma.

Seth M. Pollack, MD, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the potential impact that radiomics could have on the treatment landscape of sarcoma.

Radiomics is still somewhat of a brand new field, says Pollack, and researchers are only just beginning to scratch the surface. Although radiomics does not currently have an established role in the management of patients, its potential application this space is still exciting.

Radiomics works by quantifying complex aspects of tumor images related to tumor biology. Pollack explains that it is essentially a way to look at images that takes the viewer out of it, allowing the computer to look for elements to the radiologic files that a person wouldn’t be able to see.

In terms of the potential clinical impact of this tool, he says this could represent a promising method for predicting patient outcomes. Once radiomics is validated in a reliable way, then the exciting work will ensue, in which researchers can use these predictive features to choose which treatment a patient is best suited for.

Related Videos
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh